Pneumococcal vaccination such as PCV13 and PPV23 is recommended in RA patients due to the substantial risk of pneumococcal infections. However, previous studies have reported …
Current treatment guidelines for RA hail janus kinase inhibitors (JAKis) alongside biologics as effective therapeutic options for patients refractory to initial conventional synthetic DMARDs. A …
Vitamin K-dependent protein S (PROS) can function as a prospective biomarker in predicting response to the methotrexate (MTX)/etanercept (ETA) combination in patients with rheumatoid arthritis …
Literature studies validate the role of hematological indices as reliable markers for the assessment of disease activity in rheumatoid arthritis (RA). A recent study published …
Tacrolimus administered along with biological disease-modifying anti-rheumatic drugs (bDMARDs) showed elevated retention rates compared to bDMARDs therapy without tacrolimus (TAC) or methotrexate (MTX), according to …
The findings of a 24-week, phase 2 trial published in the recent issue of the New England Journal of Medicine have demonstrated that iberdomide at …
Translational study findings have corroborated the role of granulocyte-macrophage colony-stimulating factor (GM-CSF) in upregulating TH1/TH17 pathways and pathogenesis in temporal arteries of patients with giant …
Janus kinase inhibitor, baricitinib, is found to be beneficial in enhancing disease-modifying effects in patients with rheumatoid arthritis, according to the findings published in Annals of …
A study published in the Journal of Translational Autoimmunity by experts has acknowledged the need for identification of myositis-specific antibodies (MSA) and myositis-associated antibodies (MAA) …